Publications by authors named "E Buxo"
Article Synopsis
- A retrospective study was conducted across 20 hospitals in Spain to analyze the use and effectiveness of ramucirumab in treating advanced gastric cancer (AGC) and gastroesophageal junction adenocarcinoma (GEJ) in patients between December 2015 and December 2018.
- The study included 317 patients, with the majority receiving a combination treatment of ramucirumab and paclitaxel; most patients were around 62.5 years old and predominantly male.
- Results showed that the median progression-free survival was 3.9 months for combination therapy and 2.0 months for monotherapy, while overall survival was 7.4 months and 4.3 months, respectively, aligning with existing
Background: Second-line treatments boost overall survival in advanced gastric cancer (AGC). However, there is a paucity of information as to patterns of use and the results achieved in actual clinical practice.
Materials And Methods: The study population comprised patients with AGC in the AGAMENON registry who had received second-line.
Purpose: The outcome of locally advanced adenocarcinoma of the esophagogastric junction (AEG) treated with preoperative chemoradiotherapy is heterogeneous, and favorable response to this treatment is a key factor in the patient's prognosis. The aim of this study was to evaluate F-FDG PET/CT in assessing metabolic response in patients with AEG.
Materials And Methods: This prospective study evaluated all consecutive patients with potentially operable locally advanced AEG who were candidates for neoadjuvant chemoradiotherapy.
Background: Treatment with nab-paclitaxel plus gemcitabine increases survival in patients with metastatic pancreatic cancer. However, the assessment of treatment efficacy and safety in non-selected patients in a real-life setting may provide useful information to support decision-making processes in routine practice.
Methods: Retrospective, multicenter study including patients with metastatic pancreatic cancer, who started first-line treatment with nab-paclitaxel plus gemcitabine between December 2013 and June 2015 according to routine clinical practice.
Objectives: In the EXTREME trial, a combination of cisplatin or carboplatin plus 5-fluorouracil (5-FU) and cetuximab was superior to cisplatin/carboplatin plus 5-FU for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). With the aim of improving fluoropyrimidine-related tolerance without decreasing its efficacy, the safety and efficacy of carboplatin plus the oral fluoropyrimidine tegafur and cetuximab were investigated.
Methods: A retrospective analysis of 104 patients with recurrent or metastatic HNSCC was conducted.